MAPK pathway activity plays a key role in programmed death ligand-1 expression of EGFR wild-type non-small cell lung adenocarcinoma cells

@inproceedings{Stutvoet2018MAPKPA,
  title={MAPK pathway activity plays a key role in programmed death ligand-1 expression of EGFR wild-type non-small cell lung adenocarcinoma cells},
  author={Thijs S Stutvoet and Arjan Kol and Ege de Vries and Marco de Bruyn and Rudolf S. N. Fehrmann and Anton G. T. Terwisscha van Scheltinga and Steven A. De Jong},
  year={2018}
}
3 Citations
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
TLDR
By both decreasing the incidence of CIM and improving quality of life, trilaciclib has the potential to allow patients receiving chemotherapy for ES-SCLC, including patients who are older or more vulnerable to CIM, to receive chemotherapy on schedule and at standard-of-care doses, and to improve the experience for patients receiving cancer treatment.
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
TLDR
Integrated analyses of preclinical and clinical data informed selection of the recommended Phase II dose (RP2D) used in trilaciclib trials in extensive-stage small cell lung cancer (ES-SCLC), and 240 mg/m2 was selected as the RP2D based on PK and relevant safety data.
The RANK–RANKL axis: an opportunity for drug repurposing in cancer?
TLDR
The role of RANK/RANKL in tumourigenesis is reviewed, including effects on tumour initiation, progression and metastasis and the impact of Ranks/RanksL on tumours immunology and immune evasion is considered.